File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Viral Hepatitis (+Antiviral Therapy) HBsAg and HBV DNA levels guiding entecavir cessation in HBeAg-negative chronic hepatitis B
Title | Viral Hepatitis (+Antiviral Therapy) HBsAg and HBV DNA levels guiding entecavir cessation in HBeAg-negative chronic hepatitis B |
---|---|
Authors | |
Keywords | hepatitis B nucleoside analogue treatment cessation HBsAg |
Issue Date | 2013 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH |
Citation | The 2013 Asian Pacific Digestive Week & World Congress of Gastroenterology (APDW/WCOG), Shanghai, China, 21-24 September 2013. In Journal of Gastroenterology and Hepatology, 2013, v. 28 suppl. 3, p. 414, abstract no. P1035 How to Cite? |
Abstract | Objective: The role of hepatitis B surface antigen (HBsAg) and HBV
DNA levels in predicting virologic kinetics after nucleoside analogue cessation
has not been well-investigated. Methods: Following APASL
guidelines, entecavir was stopped in HBeAg-negative patients treated for
≥2 years and undetectable HBV DNA levels on ≥3 separate occasions 6
months apart before treatment cessation. HBsAg and HBV DNA levels
were monitored at every 6–12 weeks for 1 year. Entecavir was restarted
if virologic relapse (defined HBV DNA >2,000 IU/mL) occurred.
Results: 184 patients (mean age 53.9 years, 67.9% male) were recruited.
The mean baseline HBsAg level was 2.86 (SD ± 0.56) log IU/mL. Mean
duration of entecavir therapy before cessation was 3.06 (SD ± 0.63) years.
At the time of writing, 168 (91.3%) and 119 (72.6%) patients have been
followed up for 24 and 36 weeks respectively. Cumulative rates of virologic
relapse, calculated using the Kaplan-Meier method, were 75.9% and
86.9% at weeks 24 and 36 respectively. Among patients with at least 24
weeks of follow-up, patients without virologic relapse (n = 25), when
compared to patients with virologic relapse (n = 143), had a higher probability
of undetectable viremia at week 12 off-treatment (64.0% and 18.2%
respectively, p < 0.001). Mean HBsAg levels at entecavir commencement,
entecavir cessation and the mean rate of HBsAg reduction during entecavir
therapy had no association with virologic relapse (p = 0.738, 0.829 and
0.605 respectively). Off-treatment week-12 HBV DNA levels achieved an
AUROC of 0.766 (p < 0.001, 95%CI 0.662–0.869) in predicting virologic
relapse. Among patients with HBsAg <1,000 and <500 IU/mL at entecavir
cessation, week-12 HBV DNA achieved an AUROC of 0.811 (p = 0.004,
95%CI 0.690–0.931) and 0.868 (p = 0.004, 95%CI 0.736–0.993) respectively.
Conclusion: The combination of HBsAg levels at treatment cessation
and off-treatment HBV DNA levels could predict virologic
remission after entecavir cessation. |
Description | Poster Presentation |
Persistent Identifier | http://hdl.handle.net/10722/201273 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.179 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | en_US |
dc.contributor.author | Hui, AJ | en_US |
dc.contributor.author | Wong, VWS | en_US |
dc.contributor.author | Wong, GLH | en_US |
dc.contributor.author | Liu, K | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, RMF | en_US |
dc.contributor.author | Chan, HLY | en_US |
dc.date.accessioned | 2014-08-21T07:20:16Z | - |
dc.date.available | 2014-08-21T07:20:16Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 2013 Asian Pacific Digestive Week & World Congress of Gastroenterology (APDW/WCOG), Shanghai, China, 21-24 September 2013. In Journal of Gastroenterology and Hepatology, 2013, v. 28 suppl. 3, p. 414, abstract no. P1035 | en_US |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | http://hdl.handle.net/10722/201273 | - |
dc.description | Poster Presentation | - |
dc.description.abstract | Objective: The role of hepatitis B surface antigen (HBsAg) and HBV DNA levels in predicting virologic kinetics after nucleoside analogue cessation has not been well-investigated. Methods: Following APASL guidelines, entecavir was stopped in HBeAg-negative patients treated for ≥2 years and undetectable HBV DNA levels on ≥3 separate occasions 6 months apart before treatment cessation. HBsAg and HBV DNA levels were monitored at every 6–12 weeks for 1 year. Entecavir was restarted if virologic relapse (defined HBV DNA >2,000 IU/mL) occurred. Results: 184 patients (mean age 53.9 years, 67.9% male) were recruited. The mean baseline HBsAg level was 2.86 (SD ± 0.56) log IU/mL. Mean duration of entecavir therapy before cessation was 3.06 (SD ± 0.63) years. At the time of writing, 168 (91.3%) and 119 (72.6%) patients have been followed up for 24 and 36 weeks respectively. Cumulative rates of virologic relapse, calculated using the Kaplan-Meier method, were 75.9% and 86.9% at weeks 24 and 36 respectively. Among patients with at least 24 weeks of follow-up, patients without virologic relapse (n = 25), when compared to patients with virologic relapse (n = 143), had a higher probability of undetectable viremia at week 12 off-treatment (64.0% and 18.2% respectively, p < 0.001). Mean HBsAg levels at entecavir commencement, entecavir cessation and the mean rate of HBsAg reduction during entecavir therapy had no association with virologic relapse (p = 0.738, 0.829 and 0.605 respectively). Off-treatment week-12 HBV DNA levels achieved an AUROC of 0.766 (p < 0.001, 95%CI 0.662–0.869) in predicting virologic relapse. Among patients with HBsAg <1,000 and <500 IU/mL at entecavir cessation, week-12 HBV DNA achieved an AUROC of 0.811 (p = 0.004, 95%CI 0.690–0.931) and 0.868 (p = 0.004, 95%CI 0.736–0.993) respectively. Conclusion: The combination of HBsAg levels at treatment cessation and off-treatment HBV DNA levels could predict virologic remission after entecavir cessation. | - |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH | - |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology | en_US |
dc.rights | The definitive version is available at www3.interscience.wiley.com | - |
dc.subject | hepatitis B | - |
dc.subject | nucleoside analogue | - |
dc.subject | treatment cessation | - |
dc.subject | HBsAg | - |
dc.title | Viral Hepatitis (+Antiviral Therapy) HBsAg and HBV DNA levels guiding entecavir cessation in HBeAg-negative chronic hepatitis B | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Seto, WKW: wkseto2@hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | en_US |
dc.identifier.authority | Seto, WKW=rp01659 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.identifier.doi | 10.1111/jgh.12363_2 | en_US |
dc.identifier.hkuros | 232991 | en_US |
dc.identifier.hkuros | 232990 | - |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | suppl. 3 | en_US |
dc.identifier.spage | 414, abstract no. P1035 | en_US |
dc.identifier.epage | 414, abstract no. P1035 | en_US |
dc.publisher.place | Australia | - |
dc.identifier.issnl | 0815-9319 | - |